Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis
Provided By GlobeNewswire
Last update: Jul 9, 2025
Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye
Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design
Read more at globenewswire.com
